Search details
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Article
in English
| MEDLINE | ID: mdl-37407001
2.
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
N Engl J Med
; 386(8): 735-743, 2022 02 24.
Article
in English
| MEDLINE | ID: mdl-35196427
3.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Blood
; 142(8): 687-699, 2023 08 24.
Article
in English
| MEDLINE | ID: mdl-37390310
4.
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Blood
; 140(2): 112-120, 2022 07 14.
Article
in English
| MEDLINE | ID: mdl-35427411
5.
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.
Blood
; 138(26): 2810-2827, 2021 12 30.
Article
in English
| MEDLINE | ID: mdl-34407545
6.
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Blood
; 137(20): 2817-2826, 2021 05 20.
Article
in English
| MEDLINE | ID: mdl-33259589
7.
DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study.
Am J Hematol
; 98(5): 739-749, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36810799
8.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Article
in English
| MEDLINE | ID: mdl-33676628
9.
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.
N Engl J Med
; 381(5): 432-443, 2019 08 01.
Article
in English
| MEDLINE | ID: mdl-31365801
10.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Article
in English
| MEDLINE | ID: mdl-32688395
11.
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Haematologica
; 107(11): 2630-2640, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-35443563
12.
The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.
Haematologica
; 107(1): 134-142, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-33327712
13.
NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
J Natl Compr Canc Netw
; 20(6): 622-634, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35714675
14.
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse.
Eur J Haematol
; 108(5): 379-382, 2022 May.
Article
in English
| MEDLINE | ID: mdl-35043475
15.
Approach to a patient with "double refractory" chronic lymphocytic leukemia: "Double, double toil and trouble" (Shakespeare).
Am J Hematol
; 97 Suppl 2: S19-S25, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36125036
16.
MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Future Oncol
; 18(33): 3689-3699, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36102212
17.
Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)?
Blood
; 133(2): 121-129, 2019 01 10.
Article
in English
| MEDLINE | ID: mdl-30429158
18.
Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
Haematologica
; 106(11): 2845-2852, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-33054118
19.
The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.
Br J Haematol
; 188(6): 918-923, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31682002
20.
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.
N Engl J Med
; 377(26): 2545-2554, 2017 12 28.
Article
in English
| MEDLINE | ID: mdl-29226764